Comtan (entacapone), a new drug for advanced Parkinson's disease

Novartis is now introducing Comtan (entacapone), a new drug for advanced Parkinson's disease.

It's given to enhance the effectiveness of levodopa/carbidopa (Sinemet, etc).

Comtan is a COMT inhibitor...in the same class as Tasmar (tolcapone). But Comtan isn't expected to have the same problems with liver toxicity.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote